Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Total Assets of $96.39 million for the year ending 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +15.2% in Total Assets from 2024 to 2025.
- This data is from ELITE PHARMACEUTICALS INC /NV/'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $10.83 million | Q4 2011: $10.35 million | Q2 2012: $10.19 million | Q3 2012: $10.07 million | Q4 2012: $10.37 million | Q2 2013: $10.39 million | Q3 2013: $17.41 million | Q4 2013: $18.28 million | Q2 2014: $23.97 million | Q3 2014: $23.89 million | Q4 2014: $25.70 million | Q2 2015: $29.91 million | Q3 2015: $28.70 million | Q4 2015: $27.13 million | Q2 2016: $33.06 million | Q3 2016: $34.87 million | Q4 2016: $36.20 million | Q2 2017: $33.89 million | Q3 2017: $32.01 million | Q4 2017: $32.07 million | Q2 2018: $28.50 million | Q3 2018: $27.32 million | Q4 2018: $26.38 million | Q2 2019: $24.28 million | Q3 2019: $23.53 million | Q4 2019: $24.09 million | Q2 2020: $27.82 million | Q3 2020: $27.61 million | Q4 2020: $28.67 million | Q2 2021: $29.99 million | Q3 2021: $30.62 million | Q4 2021: $31.95 million | Q2 2022: $48.11 million | Q3 2022: $50.34 million | Q4 2022: $52.72 million | Q2 2023: $46.50 million | Q3 2023: $70.72 million | Q4 2023: $74.70 million | Q2 2024: $87.85 million | Q3 2024: $88.20 million | Q4 2024: $90.76 million | Q1 2025: $96.39 million | Q2 2025: $111.34 million | Q3 2025: $117.25 million | Q4 2025: $126.41 million.
- Over the full 15 years of available data (2011 to 2025), ELITE PHARMACEUTICALS INC /NV/'s Total Assets has grown by 717.7%.
- Historical annual values: Fiscal year 2025: $96.39 million | Fiscal year 2024: $83.65 million | Fiscal year 2023: $40.90 million | Fiscal year 2022: $35.15 million | Fiscal year 2021: $26.19 million | Fiscal year 2020: $24.96 million | Fiscal year 2019: $24.40 million | Fiscal year 2018: $30.88 million | Fiscal year 2017: $34.31 million | Fiscal year 2016: $31.67 million | Fiscal year 2015: $25.92 million | Fiscal year 2014: $24.32 million | Fiscal year 2013: $11.13 million | Fiscal year 2012: $10.31 million | Fiscal year 2011: $11.79 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: